USG Corporation (USG) failed to extend gains with the stock declining -0.18% or $-0.06 to close the day at $33.35 on light trading volume of 1.52M shares, compared to its three month average trading volume of 1.66M. The Chicago Illinois 60661 based company has been outperforming the general building materials group over the past 52 weeks, with the stock gaining 63.72%, compared to the industry which has advanced 43.04% over the same period. With RSI of 77.41, the stock should still continue to rise and get closer to its one year target estimate of $32.56, making it a hold for now.
USG Corporation, through its subsidiaries, manufactures and sells building materials worldwide. The company’s Gypsum segment manufactures and markets gypsum and related products to construct walls, ceilings, roofs, and floors of residential, commercial, and institutional buildings, as well as for various industrial applications. This segment offers gypsum panels, as well as joint compounds, corner beads, joint tapes, and plasters for wallboard joints finishing under the Sheetrock brand; cement board under the Durock brand; backerboard that includes abuse-resistant interior wall panels, tile backer boards, and flooring underlayments under the Fiberock brand; poured gypsum flooring systems under the Levelrock brand; roof boards under the Securock brand; and air-water barrier system and industrial gypsum under the ExoAir 430 brand. It also provides construction plaster products under the Red Top, Imperial, Diamond, and Supremo brands; and gypsum-based products for agricultural and industrial customers. The company’s Ceilings segment manufactures and markets interior systems products, including ceiling tiles under the Radar, Eclipse, Mars, and Halcyon brands; and ceiling grids under the Donn, DX, Fineline, Centricitee, Identitee DXI, Curvatura, and Compasso brands. Its USG Boral Building Products segment manufactures, distributes, and sells various building products, mines raw gypsum, and sells natural and synthetic gypsum. This segment offers plasterboards under the USG Boral Sheetrock brand; and ceiling suspension systems under the USG Boral NextGen, Elephant, Jayaboard, Durock, and Donn DX brands, as well as mineral fiber ceiling tiles, steel grids, and joint compounds for wall, ceiling, floor lining, and exterior systems. The company distributes its products through building material dealers, home improvement centers and other retailers, specialty wallboard distributors, and contractors. USG Corporation was founded in 1901 and is headquartered in Chicago, Illinois.
LogMeIn, Inc. (LOGM) grew with the stock adding 1.32% or $1.25 to close at $95.6 on light trading volume of 1.52M compared its three months average trading volume of 746.06K. The Boston Massachusetts 02210 based company operating under the Application Software industry has been trending up for the last 52 weeks, with the shares price now 95.1% up for the period and down by -0.49% so far this year. With price target of $113.38 and a 123.87% rebound from 52-week low, LogMeIn, Inc. has plenty of upside potential, making it a hold with a view buy.
LogMeIn, Inc. provides cloud-based services for individuals and businesses to securely connect to their workplace, colleagues, and customers. Its services include join.me, join.me pro, and join.me enterprise that are browser-based online meeting and screen sharing services; Cubby Basic, Cubby Pro, and Cubby Enterprise that are cloud-based file syncing, storage, and sharing services; and LogMeIn Pro, a remote access service. The company also provides support services, including LogMeIn Rescue, Rescue Lens, and LogMeIn Rescue+Mobile, which are Web-based remote support and customer care services offering remote support through the Internet; and BoldChat, a Web-based live chat service that helps customer service staff to directly engage and provide assistance to visitors to their organization’s Website. In addition, it offers IT management services, such as LogMeIn Central, a Web-based management console; Meldium, a password and identity management product to manage, store, and share login credentials; and AppGuru, an application management product, as well as connected products comprising Xively, a platform, which provides the infrastructure services to help businesses. Further, the company provides RemotelyAnywhere, a LAN-based systems administration product used to manage personal computers and servers from within the IT system of an enterprise; LogMeIn Backup, a service that subscribers install on two or more computers to create a backup network; LogMeIn Hamachi, a hosted virtual private network service; and LogMeIn for iOS services. It serves SMBs, IT service providers, mobile carriers, customer service centers, original equipment manufacturers, enterprise customers, and consumers. The company was formerly known as 3am Labs, Inc. and changed its name to LogMeIn, Inc. in March 2006. LogMeIn, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Radius Health, Inc. (RDUS) continued its upward trend with the stock climbing 6.78% or $3.05 to close the day at $48.06 on lower than average trading volume of 1.51M shares, compared to its three month average trading volume of 741.38K. The Waltham Massachusetts 02451 based company has been outperforming the biotechnology companies by -11.4862% for last three months and its recent losses have trimmed gains to 26.37% YTD, versus the biotechnology industry which is up 0.44% for the same period. The RSI of 64.61 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, a novel synthetic peptide analog of parathyroid hormone-related protein, which has been completed Phase III clinical development for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch that has been completed Phase II clinical trial, which is used as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator that is in preclinical stage for the treatment of breast cancer or other conditions. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; and Lonza Group Ltd., as well as clinical collaboration with Novartis Pharmaceuticals. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.